{"id":66595,"date":"2026-05-28T21:24:34","date_gmt":"2026-05-28T13:24:34","guid":{"rendered":"https:\/\/flcube.com\/?p=66595"},"modified":"2026-05-28T21:24:35","modified_gmt":"2026-05-28T13:24:35","slug":"innocare-pharma-secures-australian-tga-approval-for-hibruka-in-relapsed-refractory-mantle-cell-lymphoma-highly-selective-btk-inhibitor-expands-international-footprint","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66595","title":{"rendered":"InnoCare Pharma Secures Australian TGA Approval for Hibruka in Relapsed\/Refractory Mantle Cell Lymphoma \u2013 Highly Selective BTK Inhibitor Expands International Footprint"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>InnoCare Pharma Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9969:HKG\">HKG: 9969<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688428:SHA\">SHA: 688428<\/a>) announced that Australia&#8217;s <strong>Therapeutic Goods Administration (TGA)<\/strong> has granted marketing approval for <strong>Hibruka (orelabrutinib)<\/strong> for the treatment of adult patients with <strong>relapsed\/refractory mantle cell lymphoma (r\/r MCL)<\/strong>. The approval marks a significant milestone in the company&#8217;s international expansion strategy for its novel, highly selective Bruton&#8217;s tyrosine kinase (BTK) inhibitor.<\/p>\n\n\n\n<h2 id=\"h-regulatory-approval-summary\" class=\"wp-block-heading\">Regulatory Approval Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>InnoCare Pharma Limited (HKG: 9969, SHA: 688428)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Hibruka (orelabrutinib) \u2013 highly selective BTK inhibitor<\/td><\/tr><tr><td><strong>Regulatory Authority<\/strong><\/td><td>Therapeutic Goods Administration (TGA), Australia<\/td><\/tr><tr><td><strong>Approved Indication<\/strong><\/td><td>Relapsed\/refractory mantle cell lymphoma (r\/r MCL) in adults<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Full marketing authorization<\/td><\/tr><tr><td><strong>Key Differentiator<\/strong><\/td><td>Enhanced selectivity minimizing off-target adverse effects<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-amp-clinical-advantages\" class=\"wp-block-heading\">Product Profile &amp; Clinical Advantages<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Orelabrutinib \u2013 novel, highly selective Bruton&#8217;s tyrosine kinase (BTK) inhibitor<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Irreversible BTK inhibition with superior target specificity<\/li>\n\n\n\n<li><strong>Safety Innovation:<\/strong> Effectively avoids adverse reactions caused by off-target effects through enhanced molecular selectivity<\/li>\n\n\n\n<li><strong>Efficacy Profile:<\/strong> Significantly improved therapeutic index compared to less selective BTK inhibitors<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Oral dosing regimen<\/li>\n\n\n\n<li><strong>Development Status:<\/strong> Commercially approved in multiple markets<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-global-regulatory-landscape\" class=\"wp-block-heading\">Global Regulatory Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Market<\/th><th>Regulatory Status<\/th><th>Approved Indications<\/th><th>Reimbursement Status<\/th><\/tr><\/thead><tbody><tr><td><strong>China<\/strong><\/td><td>Fully approved<\/td><td>\u2022 First-line CLL\/SLL<br>\u2022 Previously treated CLL\/SLL<br>\u2022 r\/r MCL (\u22651 prior therapy)<br>\u2022 r\/r MZL (\u22651 prior therapy)<\/td><td>All four indications included in National Reimbursement Drug List<\/td><\/tr><tr><td><strong>Australia<\/strong><\/td><td>Newly approved<\/td><td>r\/r MCL in adults<\/td><td>Pending reimbursement assessment<\/td><\/tr><tr><td><strong>Singapore<\/strong><\/td><td>Registered<\/td><td>\u2022 r\/r MCL<br>\u2022 r\/r MZL<\/td><td>Local reimbursement determination pending<\/td><\/tr><tr><td><strong>Other International<\/strong><\/td><td>Under development\/registration<\/td><td>Various B-cell malignancies<\/td><td>N\/A<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">This multi-market approval strategy demonstrates InnoCare&#8217;s systematic approach to global commercialization, starting with comprehensive domestic approval and expanding to key international markets.<\/p>\n\n\n\n<h2 id=\"h-competitive-positioning-in-btk-inhibitor-market\" class=\"wp-block-heading\">Competitive Positioning in BTK Inhibitor Market<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Selectivity Advantage:<\/strong> Superior target specificity reduces off-target toxicities associated with earlier-generation BTK inhibitors<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> Enhanced tolerability enables longer treatment duration and improved patient compliance<\/li>\n\n\n\n<li><strong>Market Opportunity:<\/strong> Addresses growing demand for safer, more effective BTK inhibitors in B-cell malignancies<\/li>\n\n\n\n<li><strong>Therapeutic Gap:<\/strong> Provides new option for r\/r MCL patients who have exhausted standard therapies<\/li>\n\n\n\n<li><strong>Pricing Strategy:<\/strong> Premium positioning justified by improved safety-efficacy profile<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-commercial-outlook-amp-strategic-impact\" class=\"wp-block-heading\">Commercial Outlook &amp; Strategic Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Australian Market:<\/strong> Estimated 200-300 annual r\/r MCL cases represent initial commercial opportunity<\/li>\n\n\n\n<li><strong>Reimbursement Pathway:<\/strong> TGA approval enables submission for Pharmaceutical Benefits Scheme (PBS) listing<\/li>\n\n\n\n<li><strong>Regional Expansion:<\/strong> Australia approval may facilitate regulatory recognition in other Asia-Pacific markets<\/li>\n\n\n\n<li><strong>Global Validation:<\/strong> International approvals strengthen InnoCare&#8217;s position as a leading Chinese biopharmaceutical innovator<\/li>\n\n\n\n<li><strong>Pipeline Leverage:<\/strong> Success with orelabrutinib supports development of next-generation BTK inhibitors and combination strategies<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding InnoCare Pharma&#8217;s Hibruka (orelabrutinib) commercial prospects, including regulatory timelines, market access, and reimbursement expectations in Australia and other international markets. Actual results may differ due to risks including competitive dynamics, pricing negotiations, market adoption rates, and regulatory requirements in additional territories.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/688428_20260528_7CFH.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688428_20260528_7CFH.\"><\/object><a id=\"wp-block-file--media-3b0ea9dc-1688-400b-9a7c-9b5733a31a55\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/688428_20260528_7CFH.pdf\">688428_20260528_7CFH<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/688428_20260528_7CFH.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-3b0ea9dc-1688-400b-9a7c-9b5733a31a55\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced that Australia&#8217;s Therapeutic Goods Administration (TGA) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,919,327,15,920,33],"class_list":["post-66595","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-hkg-9969","tag-innocare-pharma","tag-product-approvals","tag-sha-688428","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>InnoCare Pharma Secures Australian TGA Approval for Hibruka in Relapsed\/Refractory Mantle Cell Lymphoma \u2013 Highly Selective BTK Inhibitor Expands International Footprint - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced that Australia&#039;s Therapeutic Goods Administration (TGA) has granted marketing approval for Hibruka (orelabrutinib) for the treatment of adult patients with relapsed\/refractory mantle cell lymphoma (r\/r MCL). The approval marks a significant milestone in the company&#039;s international expansion strategy for its novel, highly selective Bruton&#039;s tyrosine kinase (BTK) inhibitor.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66595\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InnoCare Pharma Secures Australian TGA Approval for Hibruka in Relapsed\/Refractory Mantle Cell Lymphoma \u2013 Highly Selective BTK Inhibitor Expands International Footprint\" \/>\n<meta property=\"og:description\" content=\"InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced that Australia&#039;s Therapeutic Goods Administration (TGA) has granted marketing approval for Hibruka (orelabrutinib) for the treatment of adult patients with relapsed\/refractory mantle cell lymphoma (r\/r MCL). The approval marks a significant milestone in the company&#039;s international expansion strategy for its novel, highly selective Bruton&#039;s tyrosine kinase (BTK) inhibitor.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66595\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-28T13:24:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-28T13:24:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66595#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66595\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"InnoCare Pharma Secures Australian TGA Approval for Hibruka in Relapsed\\\/Refractory Mantle Cell Lymphoma \u2013 Highly Selective BTK Inhibitor Expands International Footprint\",\"datePublished\":\"2026-05-28T13:24:34+00:00\",\"dateModified\":\"2026-05-28T13:24:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66595\"},\"wordCount\":481,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"HKG: 9969\",\"InnoCare Pharma\",\"Product approvals\",\"SHA: 688428\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66595#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66595\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66595\",\"name\":\"InnoCare Pharma Secures Australian TGA Approval for Hibruka in Relapsed\\\/Refractory Mantle Cell Lymphoma \u2013 Highly Selective BTK Inhibitor Expands International Footprint - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-28T13:24:34+00:00\",\"dateModified\":\"2026-05-28T13:24:35+00:00\",\"description\":\"InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced that Australia's Therapeutic Goods Administration (TGA) has granted marketing approval for Hibruka (orelabrutinib) for the treatment of adult patients with relapsed\\\/refractory mantle cell lymphoma (r\\\/r MCL). The approval marks a significant milestone in the company's international expansion strategy for its novel, highly selective Bruton's tyrosine kinase (BTK) inhibitor.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66595#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66595\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66595#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InnoCare Pharma Secures Australian TGA Approval for Hibruka in Relapsed\\\/Refractory Mantle Cell Lymphoma \u2013 Highly Selective BTK Inhibitor Expands International Footprint\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"InnoCare Pharma Secures Australian TGA Approval for Hibruka in Relapsed\/Refractory Mantle Cell Lymphoma \u2013 Highly Selective BTK Inhibitor Expands International Footprint - Insight, China&#039;s Pharmaceutical Industry","description":"InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced that Australia's Therapeutic Goods Administration (TGA) has granted marketing approval for Hibruka (orelabrutinib) for the treatment of adult patients with relapsed\/refractory mantle cell lymphoma (r\/r MCL). The approval marks a significant milestone in the company's international expansion strategy for its novel, highly selective Bruton's tyrosine kinase (BTK) inhibitor.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66595","og_locale":"en_US","og_type":"article","og_title":"InnoCare Pharma Secures Australian TGA Approval for Hibruka in Relapsed\/Refractory Mantle Cell Lymphoma \u2013 Highly Selective BTK Inhibitor Expands International Footprint","og_description":"InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced that Australia's Therapeutic Goods Administration (TGA) has granted marketing approval for Hibruka (orelabrutinib) for the treatment of adult patients with relapsed\/refractory mantle cell lymphoma (r\/r MCL). The approval marks a significant milestone in the company's international expansion strategy for its novel, highly selective Bruton's tyrosine kinase (BTK) inhibitor.","og_url":"https:\/\/flcube.com\/?p=66595","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-28T13:24:34+00:00","article_modified_time":"2026-05-28T13:24:35+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66595#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66595"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"InnoCare Pharma Secures Australian TGA Approval for Hibruka in Relapsed\/Refractory Mantle Cell Lymphoma \u2013 Highly Selective BTK Inhibitor Expands International Footprint","datePublished":"2026-05-28T13:24:34+00:00","dateModified":"2026-05-28T13:24:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66595"},"wordCount":481,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","HKG: 9969","InnoCare Pharma","Product approvals","SHA: 688428","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66595#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66595","url":"https:\/\/flcube.com\/?p=66595","name":"InnoCare Pharma Secures Australian TGA Approval for Hibruka in Relapsed\/Refractory Mantle Cell Lymphoma \u2013 Highly Selective BTK Inhibitor Expands International Footprint - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-28T13:24:34+00:00","dateModified":"2026-05-28T13:24:35+00:00","description":"InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced that Australia's Therapeutic Goods Administration (TGA) has granted marketing approval for Hibruka (orelabrutinib) for the treatment of adult patients with relapsed\/refractory mantle cell lymphoma (r\/r MCL). The approval marks a significant milestone in the company's international expansion strategy for its novel, highly selective Bruton's tyrosine kinase (BTK) inhibitor.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66595#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66595"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66595#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"InnoCare Pharma Secures Australian TGA Approval for Hibruka in Relapsed\/Refractory Mantle Cell Lymphoma \u2013 Highly Selective BTK Inhibitor Expands International Footprint"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66595","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66595"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66595\/revisions"}],"predecessor-version":[{"id":66597,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66595\/revisions\/66597"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66595"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66595"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66595"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}